Peng Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Peng Wang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Zhen Chen
Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
3 shared publicationsHai-Yan Dai
Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
1 shared publicationKun Wang
Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
1 shared publicationLian-Yu Chen
Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
1 shared publicationLu-Ming Liu
1 shared publicationSong Gao
Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
1 shared publication
Latest Publications
- 1 September 2013
- Published by SAGE Publications in OMICS: A Journal of Integrative Biology
- Vol. 17 (9) , 451-459
Traditional Chinese Medicine ZHENG and OMICS Convergence: A Systems Approach to Post-Genomics Medicine in a Global World
Traditional Chinese medicine (TCM) is a comprehensive system of medical practice that has been used to diagnose, treat, and prevent illnesses for more than 3000 years. ZHENG (also known as “syndrome”) differentiation remains the essence of TCM. In China, TCM shares equal status, and integrated with Western medicine in the healthcare system to treat many types of diseases. Yet, compared to biomolecular science and Western medicine, the ZHENG/TCM approach to diagnostics might appear unobjective, but offers at the same time long-standing clinical and phenotypic-rich insights. With the current globalization of life sciences and the arrival of “Big Data” research and development, these two silos of medical lore are rapidly coalescing. The applications of multi-omics strategies to TCM have begun to provide novel insights into the essence and molecular basis of TCM ZHENG. We searched the Chinese electronic databases and PubMed for published articles related to “Omics” and “TCM ZHENG” and observed a dramatic increase in studies over the past few years. In this article, we provide a timely synthesis of the lessons learned, and the emerging applications of omics science in TCM ZHENG research. We suggest that the global health scholarship and the field of “developing world Omics” can usefully draw from TCM, and vice versa.
- 1 September 2013
- Published by SAGE Publications in OMICS: A Journal of Integrative Biology
- Vol. 17 (9) , 451-459
Traditional Chinese Medicine ZHENG and OMICS Convergence: A Systems Approach to Post-Genomics Medicine in a Global World
Traditional Chinese medicine (TCM) is a comprehensive system of medical practice that has been used to diagnose, treat, and prevent illnesses for more than 3000 years. ZHENG (also known as “syndrome”) differentiation remains the essence of TCM. In China, TCM shares equal status, and integrated with Western medicine in the healthcare system to treat many types of diseases. Yet, compared to biomolecular science and Western medicine, the ZHENG/TCM approach to diagnostics might appear unobjective, but offers at the same time long-standing clinical and phenotypic-rich insights. With the current globalization of life sciences and the arrival of “Big Data” research and development, these two silos of medical lore are rapidly coalescing. The applications of multi-omics strategies to TCM have begun to provide novel insights into the essence and molecular basis of TCM ZHENG. We searched the Chinese electronic databases and PubMed for published articles related to “Omics” and “TCM ZHENG” and observed a dramatic increase in studies over the past few years. In this article, we provide a timely synthesis of the lessons learned, and the emerging applications of omics science in TCM ZHENG research. We suggest that the global health scholarship and the field of “developing world Omics” can usefully draw from TCM, and vice versa.
- Open Access
- 1 January 2012
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2012, 1-10
Tumor Microenvironment Varies under Different TCMZHENGModels and Correlates with Treatment Response to Herbal Medicine
In traditional Chinese medicine (TCM), diagnosis of pathology and choice of treatment prescriptions are based on a method of differentiation of signs and symptoms known as syndrome differentiation orZHENG. The cornerstone of TCM,ZHENG, relies on the gathering of clinical information through inspection, auscultation and olfaction, inquiry, and palpation. However, the biomolecular basis of theZHENGremains unclear. In this study, we established mouse xenograft pancreatic cancer models withShi-Re(Dampness-Heat),Pi-Xu(Spleen-Deficiency), orXue-Yu(Blood-Stasis)ZHENG, which are regarded as the three majorZHENGs in pancreatic cancer. We found that tumors of the differentZHENGmodels exhibited significantly altered cancer-associated fibroblast (CAF) proliferative activity and tumor-associated macrophage (TAM) infiltration, which led to altered levels of CAF- and TAM-derived secreted cytokines such as SDF-1 and CCL5. TheZHENGmodel type also significantly influenced tumor growth, and administration of herbal medicine to theZHENGmodel modified the tumor microenvironment. Therefore, this study partially unveiled the molecular basis of TCMZHENGin pancreatic cancer.
- 1 January 2012
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2012, 1-10
Open AccessTumor Microenvironment Varies under Different TCMZHENGModels and Correlates with Treatment Response to Herbal Medicine
In traditional Chinese medicine (TCM), diagnosis of pathology and choice of treatment prescriptions are based on a method of differentiation of signs and symptoms known as syndrome differentiation orZHENG. The cornerstone of TCM,ZHENG, relies on the gathering of clinical information through inspection, auscultation and olfaction, inquiry, and palpation. However, the biomolecular basis of theZHENGremains unclear. In this study, we established mouse xenograft pancreatic cancer models withShi-Re(Dampness-Heat),Pi-Xu(Spleen-Deficiency), orXue-Yu(Blood-Stasis)ZHENG, which are regarded as the three majorZHENGs in pancreatic cancer. We found that tumors of the differentZHENGmodels exhibited significantly altered cancer-associated fibroblast (CAF) proliferative activity and tumor-associated macrophage (TAM) infiltration, which led to altered levels of CAF- and TAM-derived secreted cytokines such as SDF-1 and CCL5. TheZHENGmodel type also significantly influenced tumor growth, and administration of herbal medicine to theZHENGmodel modified the tumor microenvironment. Therefore, this study partially unveiled the molecular basis of TCMZHENGin pancreatic cancer.
- Open Access
- 1 January 2012
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2012, 1-8
Clinical Distribution and Molecular Basis of Traditional Chinese MedicineZHENGin Cancer
In traditional Chinese medicine (TCM) clinical practice,ZHENG(also known as syndrome) helps to guide design of individualized treatment strategies. In this study, we investigated the clinical use ofZHENGin TCM-treated cancer patients by systematically analyzing data from all relevant reports in the Chinese-language scientific literature. We aimed to determine the clinicalZHENGdistributions in six common cancers (lung, liver, gastric, breast, colorectal, and pancreatic) with the expectation of uncovering a theoretical basis for TCMZHENGas a clinical cancer treatment. In addition, we also reviewed the molecular basis underlyingXue-Yu(blood stasis),Shi-Re(dampness-heat),Yin-Xu(Yin deficiency), andPi-Xu(spleen deficiency)ZHENGthat are commonly found in cancer patients. The results from our summary study provide insights into the potential utility of TCMZHENGand may contribute to a better understanding of the molecular basis of TCMZHENGin cancer.
- 1 January 2012
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2012, 1-8
Open AccessClinical Distribution and Molecular Basis of Traditional Chinese MedicineZHENGin Cancer
In traditional Chinese medicine (TCM) clinical practice,ZHENG(also known as syndrome) helps to guide design of individualized treatment strategies. In this study, we investigated the clinical use ofZHENGin TCM-treated cancer patients by systematically analyzing data from all relevant reports in the Chinese-language scientific literature. We aimed to determine the clinicalZHENGdistributions in six common cancers (lung, liver, gastric, breast, colorectal, and pancreatic) with the expectation of uncovering a theoretical basis for TCMZHENGas a clinical cancer treatment. In addition, we also reviewed the molecular basis underlyingXue-Yu(blood stasis),Shi-Re(dampness-heat),Yin-Xu(Yin deficiency), andPi-Xu(spleen deficiency)ZHENGthat are commonly found in cancer patients. The results from our summary study provide insights into the potential utility of TCMZHENGand may contribute to a better understanding of the molecular basis of TCMZHENGin cancer.
- Open Access
- 1 January 2005
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 11 (25) , 3817-3822
Current preventive treatment for recurrence after curative hepatectomy for liver metastases of colorectal carcinoma: A literature review of randomized control trials
Current preventive treatment for recurrence after curative hepatectomy for liver metastases of colorectal carcinoma: A literature review of randomized control trials
- 1 January 2005
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 11 (25) , 3817-3822
Open AccessCurrent preventive treatment for recurrence after curative hepatectomy for liver metastases of colorectal carcinoma: A literature review of randomized control trials
Current preventive treatment for recurrence after curative hepatectomy for liver metastases of colorectal carcinoma: A literature review of randomized control trials